Samsung BioLogics Co Ltd

207940: XKRX (KOR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|%WW$RzLOCK|?<Q$%LOCK|RFK$r%

Samsung Biologics Earnings: Better-Than-Expected Profit Growth Reflected in Share Price

Samsung Biologics' second-quarter revenue grew 11.5% year over year. Management raised its revenue growth guidance for 2025 to 25%-30% from 20%-25% due to improved plant utilization rates and operational efficiency.

Sponsor Center